Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

San Diego biotech Aven­zo Ther­a­peu­tics has se­cured the ex­clu­sive op­tion to in-li­cense an­oth­er as­set, this time look­ing at glob­al ex-Chi­na rights to a bis­pe­cif­ic in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER